A regenerative graft could rethink dialysis access

NCT ID NCT06329310

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing a new type of vascular graft called aXess-E for people with end-stage renal disease who need hemodialysis. The graft is made from a biodegradable polymer that is designed to be replaced by the body's own tissue over time. The study will check whether the graft is safe and works well for dialysis access in about 20 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aXess-E conduit, a biodegradable polymer-based vascular graft with nitinol reinforcement for hemodialysis access
What this could lead to
If successful, this could provide a new, regenerative option for hemodialysis access that may reduce complications compared to traditional grafts.
What could go wrong
This is an early feasibility study with only 20 participants, so results may not generalize. Risks include device-related serious adverse events such as infection, thrombosis, or graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Hospital de Santa Maria

    RECRUITING

    Lisbon, Portugal

  • Kliničko bolnički centar Zvezdara Klinika za Interne Bolesti

    RECRUITING

    Belgrade, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.